---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-218198"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2026-05-12T11:39:12+00:00"
generated_at: "2026-05-12T11:40:17.205252+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Coya Therapeutics Q1 net loss $7.2M; cash $50.7M; FDA Fast Track for COYA 302 in ALS

## Summary
- Net loss $7.2M vs $7.3M YoY; R&D expense fell to $4.1M (down $1.1M), G&A rose to $3.4M (up $1.1M).
- Cash and cash equivalents $50.7M as of March 31, 2026.
- FDA granted Fast Track Designation to COYA 302 for ALS on March 11, 2026.
- ALSTARS Phase 2 trial now in full recruitment; topline readout expected Q1 2027.
- Completed $11.1M private placement led by Dr. Reddy's ($10M) and Greenlight Capital ($1.1M).

## SEC filing metadata
- accession: 0001193125-26-218198
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2026-05-12T11:39:12+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000119312526218198/0001193125-26-218198-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000119312526218198/coya-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-218198
- JSON: https://secwatch.observer/filing/0001193125-26-218198.json
- Plain text: https://secwatch.observer/filing/0001193125-26-218198.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.